The AJMC® clinical page includes all the published content across AJMC.com, The American Journal of Managed Care® and Evidence-Based Oncology™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.
Streamlining Biomarker-Driven Therapy Decisions to Prevent Delays
July 17th 2025An expert discusses how clinicians and institutions can streamline biomarker-driven therapy decisions by establishing rapid turnaround times for biopsies and pathology results, maintaining in-house testing capabilities, coordinating efficiently between interventional radiology and pathology teams, and ensuring insurance approvals don’t delay treatment initiation for patients who may deteriorate quickly.
Watch
Navigating First-Line Therapy Guidelines and Treatment Considerations in High-Risk Cytogenetics
Panelists discuss how NCCN guidelines are expected to incorporate quadruplet-based regimens as reasonable treatment approaches for transplant-ineligible patients, while emphasizing the need for personalized treatment strategies that consider individual patient frailty and high-risk genetics rather than applying uniform approaches across all older patients.
Watch
Panelists discuss how the CEPHEUS trial demonstrated that quadruplet therapy (daratumumab, bortezomib, lenalidomide, and dexamethasone) significantly improved minimal residual disease negativity rates compared to triplet therapy in transplant-ineligible multiple myeloma patients, achieving approximately 60% vs 47% 10–5 responses while maintaining manageable safety profiles.
Watch
Place in Therapy for Oral Combinations in Relapsed/Refractory AML
July 14th 2025A panelist discusses how oral combination therapy with decitabine-cedazuridine plus venetoclax shows activity in the relapsed/refractory acute myeloid leukemia setting, achieving responses even in patients with TP53 mutations, prior venetoclax exposure, or prior transplant, though the presenter questions whether 10 days of decitabine offers advantages over the standard 5-day regimen and emphasizes that these oral therapies can effectively extend beyond frontline treatment into salvage settings.
Watch
From IV to Oral: Reshaping AML Treatment Access and Disease Burden
July 14th 2025A panelist discusses how the shift from intravenous to oral AML therapies addresses significant quality-of-life concerns by eliminating the burden of spending 7 days per month in clinics for infusions (which can consume nearly half of a patient's remaining 15-month median survival time), while also improving clinic efficiency, though implementation requires careful attention to patient adherence, insurance coverage disparities that may penalize oral medications with higher co-pays, and monitoring for drug interactions.
Watch
MD Treatment From a Managed Care Perspective
July 14th 2025Panelists discuss how payers seek good return on investment when evaluating expensive gene therapies, creating potential friction when innovative treatments come at significant costs, requiring ongoing dialogue between manufacturers, patients, payers, and physicians to determine appropriate value and access.
Watch
Leveraging Registries and Data Analytics
Panelists discuss how data systems and registries should focus on improving care quality rather than just reimbursement, with patient empowerment strategies that encourage individuals to advocate for better treatments like de-prescribing harmful medications.
Watch
Creating a Positive Culture Around Weight Discussions
Panelists discuss how organizations must create system-wide cultural changes through staff training, appropriate clinical environments, evidence-based treatment access, and incentive structures that support rather than punish providers for addressing obesity as a chronic disease.
Watch
Final Panelist Thoughts on the Management of Pulmonary Arterial Hypertension
Panelists discuss how the future of PAH treatment looks promising with potential for disease remission through reverse remodeling agents, emphasizing the need for continued research focus on patients with other forms of pulmonary hypertension and those with significant comorbidities.
Watch
Outlining the Need for Equitable Access to Care
Panelists discuss how cost-effectiveness analyses of newer therapies like sotatercept show substantial benefits in reducing clinical worsening events and potentially decreasing downstream costs through reduced hospitalizations and transplantations, supporting value-based payment models.
Watch
Corticosteroid Premedication for Infliximab Remains Unnecessarily Common
Although use of corticosteroid premedication prior to infliximab infusions is declining, it remains unnecessarily high despite limited benefit and the risk of serious adverse events from corticosteroids.
Read More
The Importance of Multidisciplinary Collaboration in the Management of Ovarian Cancer
July 8th 2025An expert discusses how multidisciplinary collaboration can be enhanced through shared knowledge of available drugs and biomarkers among oncologists and pathologists, standardized interpretation methods across different cancer types, and clear communication about trial-specific algorithms to optimize treatment plans and ensure proper biomarker assessment.
Watch
Panelists discuss how emerging therapies like CAR T cells and bispecific antibodies may transform frontline treatment by potentially replacing transplant or changing induction regimens, while considering the cost implications and need for sustainable care models.
Watch
Overcoming Payer-Related Barriers for Optimal Care in Patients With Ovarian Cancer
July 8th 2025An expert discusses how the biggest barriers to incorporating antibody-drug conjugates (ADCs) include lacking biomarker knowledge and how payer restrictions can be overcome through early biomarker testing, proper documentation of target expression levels, and following FDA or National Comprehensive Cancer Network (NCCN) guidelines to ensure patient access to appropriate therapies.
Watch
Managing Early Relapse in Transplant-Eligible MM and the Influence of Clonal Evolution
Panelists discuss how early relapse in standard-risk patients represents a failure of current risk assessment methods and may require advanced sequencing technologies to identify hidden high-risk features that traditional fluorescence in situ hybridization testing misses.
Watch